eMed

What eMed does

eMed is a Miami-headquartered telehealth company that pivoted from COVID-19 testing services (founded 2020) into an AI-enabled GLP-1 weight-management platform. Its core offering combines at-home biomarker screening (HbA1c, Creatinine, hs-CRP, GGT, Lipid Panel, Vitamin B12), an "agentic AI" adherence and outcomes layer, and guaranteed clinical results (>90% adherence, 14.2-month average duration, -25 lbs average weight loss, per internal Corporate Partner Data as of December 2025) into a single employer-channel product. The platform also extends into decentralized clinical-trial operations following the acquisition of Science 37.

The business operates a B2B2C model priced at $25 per covered life per month for employer sponsors and $99 per month for individual subscribers, with distribution anchored by named enterprise customers including TIAA, Lennar, AON, and CVS Health. In April 2026 the company launched a healthcare-worker program targeting 22 million US workers, and it maintains dual partnerships with Eli Lilly (Lilly Employer Connect) and Novo Nordisk (Novocare), alongside Cost Plus Drugs for pharmacy fulfillment. Operations are cited in both the US and UK.

The company employs 101-250 staff and is led by CEO Linda Yaccarino (formerly of X) with Tom Brady serving as Founding Chief Wellness Officer and co-owner. In March 2026 it closed a $200 million Series A at a $2 billion-plus valuation led by AON Consulting, which is also an employer customer, indicating a tightly aligned investor-distribution relationship.

Name

eMed

Legal name

eMed

Website

https://emed.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

eMed is a Miami-based telehealth AI company that delivers employer-sponsored GLP-1 weight management with at-home biomarker screening, guaranteed outcomes, and pharmacy integration for enterprise and healthcare-worker clients.

Ownership category

akta.pro rank

Product category

Digital Health / Telehealth Weight Management

NAICS

Diet and Weight Reducing Centers (812191)

SIC

Services-Health Services (8000), Services-Prepackaged Software (7372)

akta.pro primary industry

Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)

akta.pro secondary industries

Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG), Medication Pricing, Copay Assistance & Patient Financial Support Tools (HLACAKAN)

Keywords

• Telehealth platform
• GLP-1 weight management
• Employer healthcare benefits
• At-home diagnostics
• Population health

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Capitated Employer Healthcare Plans: eMed operates a capitated flat-fee model where employers pay a fixed monthly amount per covered employee ($25 per covered life per month for healthcare worker programs), enabling predictable healthcare cost budgeting and reducing exposure to GLP-1 medication price volatility and PBM markups.
2. Individual Program Fees (Healthcare Worker Exclusive): Enrolled employees pay $99 per month for all clinical services and FDA-approved GLP-1 medications as part of the exclusive healthcare worker program. This individual subscription supplements employer capitated revenue.
3. Pharmacy/Medication Fulfillment: Revenue from supplying GLP-1 medications (Wegovy, Zepbound) to members through partnerships with Novo Nordisk and Eli Lilly, integrated into the employer platform and individual programs.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

eMed operates a weight management and population health platform combining a clinically supervised GLP-1 medication program, at-home biomarker diagnostic screening, and a mobile app with 24/7 clinical support and continuous adherence monitoring. For employers, it delivers the offering under a capitated flat-fee payment model with no PBM markups and guaranteed adherence and weight-loss outcomes. For individuals, the same platform is accessed via a direct-to-consumer mobile app subscription.

Product overview

eMed operates as a unified Weight Management and Population Health Platform combining three core components: (1) a clinically supervised GLP-1 Program for weight management and chronic disease care, (2) an At Home Screening Kit for clinical biomarker assessment, and (3) an Agentic AI Platform for employer healthcare cost optimization. The platform also includes a mobile app (eMed Population Health App) available on iOS and Android, and operates under a capitated care model for employers. The company expanded through acquisition of Science 37 to integrate decentralized clinical trials. The platform is designed to maximize adherence and bend employer healthcare cost curves through integrated diagnostics, clinical support, and AI-driven cost management.

Differentiator

Problem solved

Functional benefit

Products and services

• GLP-1 Program Clinically supervised GLP-1 weight management program for employers and individuals featuring 24/7 clinical support, personalized guidance, and continuous adherence monitoring; reports over 90% member adherence and average weight loss of 25 lbs.
• At Home Screening Kit Clinical intake diagnostic kit that screens for key biomarkers including HbA1C, Creatinine, hs-CRP, GGT, Lipid Panel, and Vitamin B12 to assess metabolic health and cardiovascular risk, used as the clinical on-ramp for eMed's GLP-1 program.
• eMed Population Health Mobile App Mobile application for iOS and Android that delivers 24/7 clinical support, personalized guidance, continuous adherence monitoring, and access to GLP-1 programs and at-home diagnostic services for individual members.
• Science 37 Decentralized Clinical Trials Platform Decentralized clinical trials platform acquired by eMed that enables remote, at-home clinical study participation and strengthens the company's clinical evidence generation capabilities.

Quantifiable outcome

• 90%+ GLP-1 program member adherence rate, more than double the industry norm
• +7 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Novo NordiskcoreStrategic or Co-development PartnereMed was named a Novocare Recognized Care Provider by Novo Nordisk in January 2026, enabling eMed to deliver access to the newly FDA-approved Wegovy oral semaglutide pill (approved December 2025) — the first and only oral GLP-1 medication for chronic weight management. The partnership combines Novo Nordisk's pharmaceutical products with eMed's clinically guided care model for adherence support and long-term engagement. Novo Nordisk's clinical data showed approximately 17% average weight loss with Wegovy pill.
• Mark Cuban Cost Plus Drug CompanycoreStrategic or Co-development PartnereMed and Mark Cuban's Cost Plus Drugs announced a collaboration at SXSW 2026, under which eMed's employer customers have their GLP-1 medication needs fulfilled through Cost Plus Drugs at the lowest possible prices. Both companies positioned the partnership as aligned in 'fighting for the lowest price possible' for employers and patients, differentiating from direct-to-consumer competitors.
• Eli Lilly (Employer Connect Platform)coreStrategic or Co-development PartnereMed is listed as one of over 15 independent program administrators on Eli Lilly's Employer Connect platform, launched March 5, 2026. The platform provides Zepbound KwikPen at $449/dose across all strengths, enabling eMed to offer Lilly's GLP-1 medications to its employer customers through a structured, discounted pricing channel outside traditional PBM models.
• Science 37minorStrategic or Co-development PartnereMed acquired Science 37 to integrate decentralized clinical trial capabilities into its digital health platform. This acquisition expands eMed's clinical evidence generation capabilities and enables remote, at-home clinical study participation for members, differentiating its platform with research-grade data and evidence.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hims & Hers Health: Hims & Hers is a leading DTC telehealth platform that has expanded aggressively into GLP-1 weight-loss programs. Directly competes with eMed in the consumer-facing GLP-1 channel and serves as the primary benchmark cited for churn rates.
• Ro: Ro operates a vertically integrated telehealth platform offering GLP-1 weight management alongside men's and women's health. Direct competitor to eMed in DTC GLP-1s and frequently cited by eMed leadership as the comparison point.
• Found: Found is a weight-management program combining clinician-supervised care with medication (including GLP-1s) and behavior coaching. Highly comparable to eMed on the clinical-supervision-plus-medication model for chronic weight management.
• Calibrate: Calibrate offers a metabolic-health weight-loss program combining GLP-1 medication with coaching and clinician oversight. Comparable to eMed in combining medication management with longitudinal coaching and outcomes tracking.
• LifeMD: LifeMD is a telehealth company offering weight-management programs including GLP-1s, with employer and direct-to-consumer channels. Comparable to eMed in combining virtual clinical care, prescription medication, and DTC/employer distribution.
• WeightWatchers (WW): WW has pivoted from pure behavior-based weight loss into a clinician-supervised program that includes access to GLP-1 medications. Comparable to eMed in weight-management outcomes focus and employer channel ambitions.
• Noom: Noom is a digital weight-management platform combining behavior change, coaching, and increasingly clinician-supervised medication including GLP-1s. Comparable to eMed on chronic weight-management outcomes, adherence focus, and employer/B2B distribution.

Emerging players

• Virta Health: Virta Health delivers digitally enabled chronic-disease reversal programs, with strong evidence in type-2 diabetes and prediabetes. Comparable to eMed in the cardiometabolic, biomarker-driven chronic-disease management space that eMed is expanding into.
• Omada Health: Omada Health is a digital chronic-disease prevention and management platform sold primarily to employers and health plans, with focus on diabetes, hypertension, and behavioral health. Comparable to eMed on employer-B2B chronic-disease distribution.

Broad incumbents

• Teladoc Health: Teladoc Health is a large incumbent in virtual care with employer and health-plan channels across primary care, mental health, and chronic conditions. Comparable to eMed in employer-B2B distribution and chronic-condition management, though not GLP-1-specialized.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/emeddigitalhealthcare

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eMed